Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial

• Main Authors: Stephen Kimani, MBChB (Author), Matthew S Painschab, MD (Author), Bongani Kaimila, MBBS (Author), Edwards Kasonkanji, MPH (Author), Takondwa Zuze, MBBS (Author), Tamiwe Tomoka, MMed (Author), Maurice Mulenga, MMed (Author), Richard Nyasosela, MMed (Author), Maria Chikasema (Author), Asekanadziwa Mtangwanika (Author), Mena Chawinga (Author), Wilberforce Mhango (Author), Simon Nicholas (Author), Fred Chimzimu (Author), Coxcilly Kampani (Author), Robert Krysiak, MS (Author), Amy Lilly, MD (Author), Cara Randall, MD (Author), Ryan Seguin, MPH (Author), Katherine D Westmoreland, MD (Author), Nathan D Montgomery, MD (Author), Yuri Fedoriw, MD (Author), Satish Gopal, MD (Author)
• Format: Book
• Published: Elsevier, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, d...